Dr. Jennifer Doudna, Nobel laureate & Scribe co-founder, is one of America’s greatest innovators. Our CEO and co-founder @benjaminloakes.bsky.social spoke with @forbes.com about her unmatched impact on science and medicine. Check out Dr. Doudna’s Forbes 250 profile in the links below 👇

We achieved a second success milestone with @elilillyandcompany.bsky.social in our collaboration to advance in vivo #CRISPR-based therapies for neurological and neuromuscular disorders. Progress like this matters because patients cannot wait. More details in thread 🧵 #CRISPR #GeneEditing

Our thanks to BiopharmaTrend for highlighting our newest preprint! We detail the engineering behind our ELXR epigenetic silencing tech – including a new control layer for the CasX-based epigenetic silencer. The result: Improved precision for CRISPR-based therapeutics. Details ⬇️

Can #CRISPR genetic medicine solve cardiovascular disease? We’re advancing STX-1150 into first-in-human clinical trials to target LDL-C, one of the biggest drivers of heart disease, and reduce ASCVD risk without permanently changing the DNA. @longevitytech.bsky.social article below 👇

We’re proudly going red in support of National #WearRedDay and heart disease prevention ❤️‍🩹 Join us and learn more about what you can do to protect yourself and your loved ones by visiting: www.nhlbi.nih.gov/health/heart... #HeartDisease #OurHearts #HeartMonth

💡 During #AmericanHeartMonth, check out a thoughtful interview Scribe’s co-founder Jennifer Doudna recorded with Core Memory founder @ashleevance.bsky.social – highlighting how #CRISPR could shift current cardiometabolic disease treatment from symptom management to prevention. Links ⬇️

How do we engineer #CRISPR genetic medicines with the potency, specificity, and durability to treat not only rare disease, but also highly prevalent conditions? Our CEO @benjaminloakes.bsky.social joined the Cell & Gene Podcast to discuss. Links in the thread 🎧

As #AmericanHeartMonth approaches, we're preparing to advance a new therapy for cardiovascular disease. STX-1150 is designed to durably lower LDL-C through epigenetic silencing of PCSK9, aiming to mirror the cardioprotective effects grounded in human genetics. More in @endpts.com 👇

Another successful JPM is in the books 📕 From announcing a clinical trial for Scribe's lead cardiometabolic asset STX-1150, to speaking at events like Fierce JPM Week, check out our #JPM2026 in photos and links below.

We're pleased to announce: 📣 A first-in-human clinical trial for STX-1150, our lead cardiometabolic asset targeting PCSK9 for durable LDL-C reduction 📄 A newly released preprint detailing the engineering of our #CRISPR epigenetic silencing technology that underlies STX-1150

Happening TODAY at #JPM2026! Don’t miss our CEO @benjaminloakes.bsky.social’s presentation at the J.P. Morgan Healthcare Conference (8:30 am PT) and panel on #biotech innovation at Fierce JPM Week (3:00 pm PT). #JPM26 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Kick off JPM Week with us this Sunday! Our SVP of Development Chitra Sharma will be speaking at a roundtable showcasing CGT innovation during #JPM2026 week, along with speakers from @elilillyandcompany.bsky.social, Alphabet Health, ProBio, and more. Details below 🧬👇

Coming up next week at #JPM2026: Our CEO @benjaminloakes.bsky.social will speak at the J.P. Morgan Healthcare Conference and Fierce JPM Week. Don’t miss them on Wednesday, January 14 at 8:30 a.m. and 3:00 p.m. PT! Links in 🧵 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Wishing everyone a Happy New Year!

Check out this Singularity Hub article about Scribe's breakthrough #AHA25 data on our #CRISPR epigenetic and gene editing medicines for heart disease. Thanks to Shelly Fan for covering their potential to revolutionize how cardiometabolic disease is treated 👇 singularityhub.com/2025/11/27/c...

ICYMI, our latest data is out in Fierce Biotech. Read about our lead candidate – epigenetic silencing therapy STX-1150 – and #CRISPR gene editors STX-1200 and STX-1400, designed to safely and durably address the main lipid drivers of heart disease. Article by @megadarren.bsky.social.

Could a single treatment lower heart disease risk by up to 90%? At Scribe, we're engineering #CRISPR gene editing and epigenetic silencing therapies that target major drivers of cardiometabolic disease. Our CEO @benjaminloakes.bsky.social recently shared our progress at #TCT2025.

Our co-founder & CEO @benjaminloakes.bsky.social will present at the 44th Annual J.P. Morgan Healthcare Conference. Join us on Wednesday, January 14 at 8:30 a.m. PT to hear what we have in store for 2026. #JPM2026 #CRISPR #GeneEditing #EpigeneticEditing #CVD

Thanks to Drug Discovery News for the great coverage featuring Scribe CEO @benjaminloakes.bsky.social's thoughts on the current state and future potential of AI-assisted CRISPR technologies. Read the full piece here: www.drugdiscoverynews.com/can-ai-take-...

This week, Scribe’s Computational Genomics & Data Science Team is at @awscloud.bsky.social re:Invent 2025 for the AWS AI League Championship Finals, competing against top AI innovators nationwide. Regional champion Mohit Pandey is representing Scribe after the team’s 1st place win in SF!

As we approach #Thanksgiving, we'd like to celebrate our incredible Scribe team. Their scientific expertise, tireless dedication to advancing our mission, and home-cooked dishes at our annual potluck are just a few of the many reasons we're thankful. Happy Thanksgiving! 🦃

We’re excited to be featured in @longevitytech.bsky.social, where @mrdannysullivan.bsky.social sits down with our CEO @benjaminloakes.bsky.social to discuss how next-gen CRISPR therapies could extend lifespans by revolutionizing the treatment paradigm for CVD. Read the full piece: bit.ly/4riTDZn

📅 Join today's Fierce Biotech Cell & Gene Turning Point event! Our CEO @benjaminloakes.bsky.social will take the virtual stage at 11:30 am PT for a fireside chat exploring how CRISPR could redefine the treatment paradigm for CVD. Register for free now: www.fiercecellandgene.com

We're excited to share breakthrough preclinical data across our cardiometabolic pipeline presented at #AHA25, highlighting our comprehensive strategy to address the key drivers of #ASCVD. Thanks to Fierce Biotech‘s Darren Incorvaia for the feature: www.fiercebiotech.com/research/scr...

Scribe CEO @benjaminloakes.bsky.social will join a fireside chat at Fierce Biotech's Cell & Gene Turning Point event on Thursday, 11/20. He'll discuss how CRISPR-based therapies could help prevent, not just treat, cardiovascular disease. Register for free here: www.fiercecellandgene.com

#AHA25 Scientific Sessions are underway! Don’t miss key presentations by CSO Aarif Khakoo and SVP of Discovery Biology Maria Mirotsou. From #CRISPR gene editing to epigenetic silencing, we’ll share updates on our pipeline of therapies for cardiovascular disease.👇 @ahascience.bsky.social

🥇 Our Computational Genomics & Data Science team won 1ST PLACE in AWS AI League for Startups SF! Huge shout-out to champion Mohit Pandey and full squad for showcasing Scribe’s growing AI innovation capabilities. Thanks to @awscloud.bsky.social for inviting us and a fantastic competition.

📣 #AHA25 is almost here! We’re headed to New Orleans to share the latest on our pipeline of #CRISPR genome editing & epigenetic silencing therapies for cardiometabolic disease. Details below on 4 presentations by our CSO Aarif Khakoo & SVP of Discovery Biology Maria Mirotsou 👇

When it’s spooky season at Scribe, expect our annual #Halloween barbecue, scary and scientific costumes, and treats galore. Happy Halloween to all! 🎃

How can we transform the standard of care for heart disease? ❤️‍🩹 Join us at #TCT2025 this Saturday to hear from our CEO @benjaminloakes.bsky.social, who will share promising #CRISPR gene editing and epigenetic silencing strategies at @crfheart.bsky.social TCT MedTech Innovation Forum.

Missed our presentation on Scribe’s ELXR (epigenetic editor) technology at #ESGCT2025? Catch up with this BioWorld article highlighting how we engineered our ELXR platform for enhanced potency and its therapeutic application in durably targeting PCSK9. www.bioworld.com/articles/725...

Listen to Scribe’s co-founder, Jennifer Doudna, speak to the vision that Scribe was founded on – unlocking #CRISPR to revolutionize the standard of care for cardiometabolic disease. "I really hope that gene editing technology, like CRISPR, becomes a preventative [therapy]..." 🧵

Congrats to our CEO, @benjaminloakes.bsky.social, on being named to BioSpace’s inaugural 40 Under 40 list of exemplary biotech leaders for his vision, innovation, and commitment to advancing next-generation #CRISPR-based therapeutics that improve patient outcomes.

We’re headed to #ESGCT2025 to share our latest #CRISPR #EpigeneticEditing data. Check out our presentation on Thursday, Oct. 9! 🧬 Engineering enhanced epigenetic editors: novel repressor domains drive potent and durable therapeutic gene silencing in non-human primates

Meet Scribe at #CGMesa25 in Phoenix 🌵 Our CFO David Parrot will be onsite at the @alliancerm.bsky.social Cell & Gene Meeting on the Mesa to present updates on our work engineering #CRISPR-based medicines for cardiometabolic disease. Swing by and learn more on Monday, Oct. 6 at 1:45pm MST.

Ahead of #WorldHeartDay, Taylor Swift recently raised an important reminder: heart disease is the leading cause of death, and one person dies from it every 34 seconds. For some, including her father, a routine stress test revealed severe disease early enough to undergo surgery.

Attending the Genome Editing Therapeutics Summit? Join us Sept. 30 for the opening presentation by Kai-Yuan Chen, Scribe's Director of Data Science & Tech Platform, highlighting DeepXE: our deep learning model powering #CRISPR-CasX therapeutic gRNA design. #AI #MachineLearning

An important piece in @forbes.com by Leaps By Bayer highlighting the dangers of high cholesterol, the urgent need for solutions beyond statins, and Scribe’s advances developing #CRISPR gene editing and epigenetic silencing therapies for cardiometabolic disease. www.forbes.com/sites/juerge...

This Thursday, join us at the Oppenheimer Private Life Science Company Showcase for a virtual presentation by our CFO David Parrot. 📅 September 25, 2025 🕗 3:15pm ET 📍 Virtual ✅ Register for the event or reach out to our team at www.scribetx.com/contact

Knowing your #cholesterol could save your life. This National #CholesterolEducationMonth, stay up to date on the impact cholesterol levels have on your risk for heart disease. 👇

Attending the Bank of America Healthcare Trailblazers Private Company Conference in Boston this week? Book a meeting with Scribe CFO David Parrot to learn about our latest updates, data, and approach to advancing #CRISPR for cardiometabolic disease 👉 www.scribetx.com/contact

📣 Presenting new breakthrough data from two of our core platforms 📣 We're proud to showcase the success of our Lp(a)-lowering therapy STX-1200 and novel #AI platform, DeepXE, for next-generation #CRISPR-based therapeutics. More details in our link below 👇

At Scribe, we run on teamwork and purpose – in and out of the lab. #JPMCC 2025 marked our 4th year participating in the global J.P. Morgan Corporate Challenge. Check out our reel for highlights our team captured as they ran through San Francisco, repping our “ELXR” tech! 🧪😉

If you’ll be in New York for the Cantor Global Healthcare Conference, our CEO @benjaminloakes.bsky.social and CFO David Parrot will be on site and available for one-on-one meetings between Sept. 3-5. Interested in connecting? Reach out through our website 👉 www.scribetx.com/contact

At #ESCCongress for the latest on #CRISPR gene editing treatments for cardiometabolic disease? On Monday, our CSO Aarif Khakoo will present late-breaking preclinical data on STX-1200, our novel CRISPR-CasX based gene editing therapy to reduce elevated Lp(a) & CVD risk. Read more 👇

This fall, we are thrilled to present our latest updates on our #CRISPR genetic and epigenetic editing therapies, new machine learning approach, and corporate strategy at several premier conferences. If you’ll be at #ECCongress, #CGMesa25, and others, read on for more details 👇

What does it take to rewrite the story of disease? Our CEO @benjaminloakes.bsky.social‬ shared with @bigthink.com‬ how a mission-driven team like Scribe can redefine what is possible in medicine with #CRISPR. His insights on leadership, innovation, and bold vision 👇 bigthink.com/business/lea...

We’re proud to call Alameda our home and share with the SF Business Times the history of our space (all the way back to WWI and WWII) and ability to invest in world-class talent to help us engineer the future of medicine. Read about our #biotech community: www.bizjournals.com/sanfrancisco...

Deep learning for #CRISPR? We're presenting "DeepXE" at @cshlnews.bsky.social's Genome Engineering: CRISPR Frontiers meeting—the 1st predictive model for on-target activity of our genome editor engineered from CasX. Learn how we're tapping #AI to design efficient gRNAs for therapeutics. #CSHL

📣 New publication alert! Scribe and @ucberkeleyofficial.bsky.social scientists (Zachary Miller, Lokesh Narsineni et al.) have a paper out in the Journal of Controlled Release on a powerful new method for molecular characterization of lipid nanoparticles and mRNA packaging. Learn more below ⬇️